Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial, page-48

I agree with your figures of 16%, 20% and 27% but that is not for survival. That is for complete, pathologically demonstrated, eradication of the tumour. Completely different to what you have stated. All bar one patient survived, and her death was not due to PTX200.
Partial response in all other patients. What would be interesting to me is the level of partial response, i.e. how much has the tumour shrunk and over what time period.
The other excellent news here is that survival times range upto 40 months with an average of 22.4 months.
In my opinion these results are hugely promising, like everybody else, especially the patients, you would like a 100% pCR, but that is utopian. A higher level of pCR would have been better, obviously, but these results are not average, in my humble opinion.